Medical Condition News

RSS

Improved glycemic control can slow progression of ESRD in type 1 diabetic people

People with type 1 diabetes who have developed kidney complications can slow the progression of their complications by improving control of their glycemic (blood glucose) levels over the long term.

6 Jun 2014

SGC and CHDI Foundation collaborate to discover new drug targets for Huntington's disease

The Structural Genomics Consortium (SGC) and CHDI Foundation have entered into a unique open-access research collaboration to discover and characterize new drug targets for Huntington's disease (HD) using structural and chemical biology In this first partnership of its kind, SGC and CHDI have explicitly agreed not to file for patents on any of the collaborative research and to make all reagents and knowledge available without restriction to the wider research community, including pharmaceutical, biotech, and academic research groups.

6 Jun 2014

Researchers find that protein serves as on-off switch for "beigeing" of fat

Scientists this week reported that a molecular pathway called mTORC1 controls the conversion of unhealthy white fat into beige fat, an appealing target for increasing energy expenditure and reducing obesity.

6 Jun 2014

Lack of O2 in fat cells triggers inflammation and insulin resistance in obesity

Researchers at the University of California, San Diego School of Medicine have, for the first time, described the sequence of early cellular responses to a high-fat diet, one that can result in obesity-induced insulin resistance and diabetes.

6 Jun 2014

About MS booklet now available as a printed and online publication

The Multiple Sclerosis Association of America is pleased to announce that the newly published About MS booklet is now available as both a printed and online publication.

6 Jun 2014

Discovery may lead to relief for victims of range of neurological disorders

University of Toronto biologists leading an investigation into the cells that regulate proper brain function, have identified and located the key players whose actions contribute to afflictions such as epilepsy and schizophrenia.

6 Jun 2014

NCOA brings innovative online support program to help people manage type 2 diabetes

Under a unique collaboration, the National Council on Aging with support from the Bristol-Myers Squibb Foundation and WellPoint are—for the first time—bringing a proven and affordable face-to-face and online support program to help people manage their Type 2 diabetes.

6 Jun 2014

Researchers take step toward restoring natural, high-fidelity vision to blind people

In laboratory tests, researchers have used electrical stimulation of retinal cells to produce the same patterns of activity that occur when the retina sees a moving object. Although more work remains, this is a step toward restoring natural, high-fidelity vision to blind people, the researchers say.

6 Jun 2014

ImStem successfully treats animal model of multiple sclerosis using hESC

ImStem Biotechnology, Inc. (ImStem) announced today it has successfully treated an animal model of multiple sclerosis (MS) using human embryonic stem cells (hESC) derived mesenchymal stem cells (MSCs), called hES-MSCs.

6 Jun 2014

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Ocugen, Inc. and the University of Colorado today announced exclusive license agreements that allow for Ocugen to continue developing two drug candidates for the treatment for ophthalmology indications, and that one of the assets, OCU100, recombinant lens epithelium derived growth factor 1-326 (LEDGF1-326), received orphan-drug status from the U.S. Food and Drug Administration for treatment of retinitis pigmentosa (RP), a rare eye disease.

6 Jun 2014

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

Tolero Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company developing treatments for oncology and blood disorders, reported positive interim results from an ongoing, randomized Phase 2 clinical trial of its lead drug candidate, alvocidib, in combination with cytarabine plus mitoxantrone for previously untreated acute myeloid leukemia (AML) patients.

6 Jun 2014

MolecularHealth launches innovative oncology program for employers

MolecularHealth announced today the official launch of MolecularHealth COPE (Corporate Oncology Program for Employers), powered by its cancer treatment decision support offering, TreatmentMAP.

6 Jun 2014

Naloxegol holds hope for opioid-induced constipation

Pain medicines often lead to constipation for patients seeking long-term pain relief, but an investigational once-daily drug may help, according to study led by the University of Michigan Health System.

5 Jun 2014

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Caris Life Sciences and investigators from Inova Fairfax Hospital presented the first clinical outcomes data presentation from the Caris Registry™ at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend.

5 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for acute, life-threatening neurological conditions, today announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962.

5 Jun 2014

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics, a privately held company dedicated to bringing new anti-cancer therapies to market, announced today (June 4) that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.

5 Jun 2014

Cook Medical introduces Zilver PTX Drug-Eluting Peripheral Stent in Canada

Cook Medical launched its Zilver PTX Drug-Eluting Peripheral Stent in Canada at the Canadian Interventional Radiology Association (CIRA) meeting in Montreal, Canada. It's the first drug-coated stent in Canada indicated to treat peripheral arterial disease (PAD) in the superficial femoral artery (SFA).

From COOK MEDICAL INC. 5 Jun 2014

Navigated brain stimulation system may help improve motor function for people recovering from stroke

Researchers at Shepherd Center are studying whether stimulating the brain before rehabilitation could yield greater gains in motor function for people recovering from stroke.

5 Jun 2014

Many heroin users transitioned from prescription opioids, finds study

A research paper published in the May 28, 2014 issue of JAMA Psychiatry a paper entitled "The Changing Face of Heroin Use in the United States A Retrospective Analysis of the Past 50 Years" concluded that heroin abuse has left low-income urban areas and has become prevalent in more affluent suburbs and rural areas with mostly white populations.

5 Jun 2014

Medical Condition News

Improved glycemic control can slow progression of ESRD in type 1 diabetic people

SGC and CHDI Foundation collaborate to discover new drug targets for Huntington's disease

Researchers find that protein serves as on-off switch for "beigeing" of fat

Lack of O2 in fat cells triggers inflammation and insulin resistance in obesity

About MS booklet now available as a printed and online publication

Discovery may lead to relief for victims of range of neurological disorders

NCOA brings innovative online support program to help people manage type 2 diabetes

Researchers take step toward restoring natural, high-fidelity vision to blind people

ImStem successfully treats animal model of multiple sclerosis using hESC

Ocugen's OCU100 gets FDA orphan drug designation for treatment of retinitis pigmentosa

Tolero Pharmaceuticals reports positive interim results from alvocidib Phase 2 trial for AML treatment

MolecularHealth launches innovative oncology program for employers

Naloxegol holds hope for opioid-induced constipation

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Cook Medical introduces Zilver PTX Drug-Eluting Peripheral Stent in Canada

Navigated brain stimulation system may help improve motor function for people recovering from stroke

Many heroin users transitioned from prescription opioids, finds study

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News